Allegheny Health Network | Association Partnerships

In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.

In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.

Gene G. Finley, MD, discusses some of the challenges seen when treating patients with small cell lung cancer.

Gene G. Finley, MD, discusses the potential use of molecular testing to improve outcomes for patients with relapsed small cell lung cancer.

An update from Allegheny Health Network's Neuroscience Institute.

In an interview with Targeted Oncology, Benny Weksler, MD, MBA, reviews key trials that have recently influenced the standard of care for patients with stage IB to IIIB NSCLC.

Gene G. Finley, MD, explains the use of conventional chemotherapy in the small cell lung cancer space.

During a tweet chat, Shifeng S. Mao, MD, PhD and Targeted Oncology Twitter followers discussed the case of 59-year-old woman with clear-cell renal cell carcinoma ad best treatment options for the patient.

In an interview with Targeted Oncology, Gene G. Finley discussed the many wins and losses experts have seen in the small cell lung cancer space. He also explained his hopes for the future of this space.

In an interview with Targeted Oncology, Larisa Greenberg, MD discussed the current state of thyroid cancer, challenges, and where the field is headed in the near future.

Gene G. Finley, MD, explains a questions lingering on the benefit of immunotherapy in patients with small call lung cancer.

Salman Fazal, MD, explains how to lower the risk of graft-versus-host disease in patients who undergo allogeneic stem cell transplant.

In an interview with Targeted Oncology following the tweet chat, Cyrus M. Khan, MD, discussed the emerging and recent data he thinks could influence the case we discussed.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

In an interview with Targeted Oncology™, Cyrus M. Khan, MD, discussed new strategies for the treatment of mantle cell lymphoma and needs for the future.

For Thyroid Cancer Awareness Month, Warren C. Swegal, MD, highlights the changing landscape, important trials, sequencing, and future of this setting.

In an interview with Targeted Oncology following the tweet chat, Warren Swegal, MD, discussed the key takeaways from the discussion, including his thoughts on the case and what he hopes will be addressed in the future of the thyroid cancer space.

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.

For sarcoma awareness month, Lisa Ercolano, MD, discusses the need for a multidisciplinary approach to treating patients with osteosarcoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

David L. Bartlett, MD, discussed the adoption of key immunotherapies and how exploration of the tumor microenvironment and immune environment is opening new approaches to treatment in an interview with Targeted Oncology.

During an interview with Targeted Oncology, Shifeng S. Mao, MD, discussed what current and upcoming clinical studies have led to improvements in how physicians treat urothelial cancer.

Allegheny Health Network and Illumina, Inc. announced a collaborative effort to assess their in-house comprehensive genomic testing to analyze the role of genetic tests in improving cancer care.

In an interview with Targeted Oncology, Stephen M. Karlovits, MD, discussed key developments that researchers have made in the primary brain tumor treatment landscape in recent years and upcoming trials with potential to improve outcomes for patients.

During a Targeted Oncology case-based roundtable event, Thomas C. Krivak, MD, discussed the results of studies of PARP inhibition for patients with advanced ovarian cancer.

The evolving landscape for treating multiple myeloma has seen significant improvement for patients, giving them better options. One of the key regimens added to this landscape is the use of a new quadruplet regimen.

Prerna Mewawalla, MD, looks back at a decade of advancements in the multiple myeloma space.

Nathan Bahary, MD, discussed with Targeted Oncology how the cholangiocarcinoma treatment paradigm has changed and what is on the horizon for treatment and care of patients.

Andrea Moreira, MD, a board-certified plastic surgeon specializing in the use of advanced techniques in breast reconstruction, has joined Allegheny Health Network.

Jill Dietz, MD, FACS, a nationally recognized breast surgeon and leader in the development of innovative, recently joined Allegheny Health Network Cancer Institute.